表紙
市場調査レポート

卵巣癌:パイプライン製品の分析

Ovarian Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229719
出版日 ページ情報 英文 1698 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
卵巣癌:パイプライン製品の分析 Ovarian Cancer - Pipeline Review, H2 2015
出版日: 2015年12月31日 ページ情報: 英文 1698 Pages
概要

卵巣癌の大多数は、卵巣の上皮(外膜)に発生します。卵巣癌の兆候や症状には、骨盤の不快感や痛み、消化不良、悪心、便秘といった排便サイクルの変化、食欲不振、腰痛などがあります。この疾患の素因には、加齢と家系が大きくかかわっています。

当レポートでは、卵巣癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

卵巣癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

卵巣癌:企業で開発中の治療薬

卵巣癌:大学/機関で研究中の治療薬

卵巣癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

卵巣癌:企業で開発中の製品

卵巣癌:大学/機関で研究中の製品

卵巣癌の治療薬開発に従事している企業

卵巣癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

卵巣癌:最近のパイプライン動向

卵巣癌:休止中のプロジェクト

卵巣癌:開発が中止された製品

卵巣癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7416IDB

Summary

Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ovarian Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Ovarian Cancer Overview
  • Therapeutics Development
  • Ovarian Cancer - Therapeutics under Development by Companies
  • Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
  • Ovarian Cancer - Pipeline Products Glance
  • Ovarian Cancer - Products under Development by Companies
  • Ovarian Cancer - Products under Investigation by Universities/Institutes
  • Ovarian Cancer - Companies Involved in Therapeutics Development
  • Ovarian Cancer - Therapeutics Assessment
  • Drug Profiles
  • Ovarian Cancer - Recent Pipeline Updates
  • Ovarian Cancer - Dormant Projects
  • Ovarian Cancer - Discontinued Products
  • Ovarian Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ovarian Cancer, H2 2015
  • Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Development by Companies, H2 2015 (Contd..12)
  • Number of Products under Development by Companies, H2 2015 (Contd..13)
  • Number of Products under Development by Companies, H2 2015 (Contd..14)
  • Number of Products under Development by Companies, H2 2015 (Contd..15)
  • Number of Products under Development by Companies, H2 2015 (Contd..16)
  • Number of Products under Development by Companies, H2 2015 (Contd..17)
  • Number of Products under Development by Companies, H2 2015 (Contd..18)
  • Number of Products under Development by Companies, H2 2015 (Contd..19)
  • Number of Products under Development by Companies, H2 2015 (Contd..20)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Development by Companies, H2 2015 (Contd..19)
  • Products under Development by Companies, H2 2015 (Contd..20)
  • Products under Development by Companies, H2 2015 (Contd..21)
  • Products under Development by Companies, H2 2015 (Contd..22)
  • Products under Development by Companies, H2 2015 (Contd..23)
  • Products under Development by Companies, H2 2015 (Contd..24)
  • Products under Development by Companies, H2 2015 (Contd..25)
  • Products under Development by Companies, H2 2015 (Contd..26)
  • Products under Development by Companies, H2 2015 (Contd..27)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015
  • Ovarian Cancer - Pipeline by 4SC AG, H2 2015
  • Ovarian Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
  • Ovarian Cancer - Pipeline by AB Science SA, H2 2015
  • Ovarian Cancer - Pipeline by AbbVie Inc., H2 2015
  • Ovarian Cancer - Pipeline by Abeona Therapeutics, Inc. , H2 2015
  • Ovarian Cancer - Pipeline by AbGenomics International, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Adaptimmune Limited, H2 2015
  • Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2015
  • Ovarian Cancer - Pipeline by Advantagene, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Advaxis, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015
  • Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
  • Ovarian Cancer - Pipeline by Agilvax, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Alchemia Limited, H2 2015
  • Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
  • Ovarian Cancer - Pipeline by Almac Discovery Limited, H2 2015
  • Ovarian Cancer - Pipeline by Ambrx, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Amgen Inc., H2 2015
  • Ovarian Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
  • Ovarian Cancer - Pipeline by ANP Technologies, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Antoxis Limited, H2 2015
  • Ovarian Cancer - Pipeline by Aphios Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Aposense Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Aprea AB, H2 2015
  • Ovarian Cancer - Pipeline by arGEN-X BV, H2 2015
  • Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H2 2015
  • Ovarian Cancer - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by ArQule, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Array BioPharma Inc., H2 2015
  • Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
  • Ovarian Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Astellas Pharma Inc., H2 2015
  • Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2015
  • Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
  • Ovarian Cancer - Pipeline by AVAX Technologies, Inc., H2 2015
  • Ovarian Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2015
  • Ovarian Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015
  • Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
  • Ovarian Cancer - Pipeline by Bayer AG, H2 2015
  • Ovarian Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
  • Ovarian Cancer - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015
  • Ovarian Cancer - Pipeline by BioAtla, LLC, H2 2015
  • Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2015
  • Ovarian Cancer - Pipeline by BioMoti Limited, H2 2015
  • Ovarian Cancer - Pipeline by Bionomics Limited, H2 2015
  • Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Bioo Therapeutics, H2 2015
  • Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Ovarian Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015
  • Ovarian Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015
  • Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2015
  • Ovarian Cancer - Pipeline by Cavion LLC, H2 2015
  • Ovarian Cancer - Pipeline by cCAM Biotherapeutics Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2015
  • Ovarian Cancer - Pipeline by Celsion Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Celyad SA, H2 2015
  • Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2015
  • Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Chikujee Therapeutics, H2 2015
  • Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2015
  • Ovarian Cancer - Pipeline by Clevexel Pharma SAS, H2 2015
  • Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
  • Ovarian Cancer - Pipeline by CohBar, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Commence Bio, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Compliment Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • Ovarian Cancer - Pipeline by CritiTech, Inc., H2 2015
  • Ovarian Cancer - Pipeline by CTI BioPharma Corp., H2 2015
  • Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by CytRx Corporation, H2 2015
  • Ovarian Cancer - Pipeline by CZ BioMed Corp, H2 2015
  • Ovarian Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
  • Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015
  • Ovarian Cancer - Pipeline by EirGenix Inc., H2 2015
  • Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2015
  • Ovarian Cancer - Pipeline by Endocyte, Inc., H2 2015
  • Ovarian Cancer - Pipeline by EntreChem, S.L., H2 2015
  • Ovarian Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Exelixis, Inc., H2 2015
  • Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Fortress Biotech, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Fujifilm Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Galileo Research s.r.l., H2 2015
  • Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H2 2015
  • Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
  • Ovarian Cancer - Pipeline by Genentech, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Genmab A/S, H2 2015
  • Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Ovarian Cancer - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
  • Ovarian Cancer - Pipeline by GlycoNex Inc., H2 2015
  • Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2015
  • Ovarian Cancer - Pipeline by GP Pharm, S.A., H2 2015
  • Ovarian Cancer - Pipeline by Gradalis Inc., H2 2015
  • Ovarian Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Heat Biologics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Horizon Pharma Plc, H2 2015
  • Ovarian Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Ignyta, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by IMMD Inc., H2 2015
  • Ovarian Cancer - Pipeline by Immune Design Corp., H2 2015
  • Ovarian Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015
  • Ovarian Cancer - Pipeline by ImmunoGen, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Immunomedics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Immunovaccine, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Incyte Corporation, H2 2015
  • Ovarian Cancer - Pipeline by Inflection Biosciences Limited, H2 2015
  • Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2015
  • Ovarian Cancer - Pipeline by Innate Pharma SA, H2 2015
  • Ovarian Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Inventiva SAS, H2 2015
  • Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2015
  • Ovarian Cancer - Pipeline by Juno Therapeutics Inc., H2 2015
  • Ovarian Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Laboratoire HRA Pharma, H2 2015
  • Ovarian Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
  • Ovarian Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2015
  • Ovarian Cancer - Pipeline by Lipocure Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015
  • Ovarian Cancer - Pipeline by Mabion SA, H2 2015
  • Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015
  • Ovarian Cancer - Pipeline by MacroGenics, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015
  • Ovarian Cancer - Pipeline by Medestea Research & Production S.p.A., H2 2015
  • Ovarian Cancer - Pipeline by MediaPharma s.r.l., H2 2015
  • Ovarian Cancer - Pipeline by MedImmune, LLC, H2 2015
  • Ovarian Cancer - Pipeline by Medivation, Inc., H2 2015
  • Ovarian Cancer - Pipeline by MEI Pharma, Inc., H2 2015
  • Ovarian Cancer - Pipeline by Merck & Co., Inc., H2 2015
  • Ovarian Cancer - Pipeline by Merck KGaA, H2 2015
  • Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015

List of Figures

  • Number of Products under Development for Ovarian Cancer, H2 2015
  • Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top